Gland Pharma Limited

GLAND

INE068V01023

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:29 2024-05-29 EDT			5-day change	1st Jan Change
1,861 ^INR	+2.56%		+3.79%	-3.30%

05-24	Gland Pharma Gets Zero Observations from US FDA for API Facility in Andhra Pradesh, India	MT
05-23	Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy	MT

Gland Pharma Limited Announces Xiaohui Guan and Yifang Wu Not Offer for Reappointment as Directors

August 26, 2022 at 08:40 am

Gland Pharma Limited announced that at the 44th AGM (Notice) dated August 01, 2022 will not be taken up for voting as Ms. Xiaohui Guan and Mr. Yifang Wu, did not offer themselves for reappointment as Directors in the 44th AGM.

Latest news about Gland Pharma Limited

Gland Pharma Gets Zero Observations from US FDA for API Facility in Andhra Pradesh, India	05-24	MT
Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy	05-23	MT
Gland Pharma Posts Surge in Fiscal Q4 Consolidated Net Profit	05-23	MT
Gland Pharma Limited Board Recommends Final Dividend for the Fiscal Year Ending March 31, 2024	05-22	CI
Gland Pharma Gets US FDA's Approval for Generic ALS Drug	05-07	MT
Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection	05-07	MT
KKR to buy India's Healthium Medtech at $839 million valuation, sources say	05-06	RE
Gland Pharma Names COO	04-29	MT
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	04-29	CI
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges	04-29	MT
Gland Pharma Receives Approval for Cetrorelix Acetate for Injection	04-29	CI
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	04-08	CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	04-08	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	04-06	CI
Gland Pharma COO, Chief Technical Officer Step Down	03-25	MT
Gland Pharma Limited Announces Change in Management	03-25	CI
Gland Pharma Names New President of Phixen Subsidiary	02-27	MT
Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy	02-15	MT
Gland Pharma's Consolidated Profit Drops in Fiscal Q3	02-15	MT
Transcript : Gland Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024	02-14
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Indian shares set to open lower as hot US inflation spurs rate worries	02-13	RE
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit	11-24	MT
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	11-17	CI
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug	11-15	MT

Chart Gland Pharma Limited

Duration

Period

More charts

Company Profile

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

Sector

Pharmaceuticals

Calendar

2024-07-16 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Gland Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,815 INR

Average target price

1,834 INR

Spread / Average Target

+1.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAND PHARMA LIMITED	-3.30%	3.59B
ELI LILLY AND COMPANY	+38.96%	727B
NOVO NORDISK A/S	+30.80%	592B
JOHNSON & JOHNSON	-7.82%	347B
MERCK & CO., INC.	+15.29%	319B
ABBVIE INC.	+0.33%	274B
ASTRAZENECA PLC	+12.34%	238B
NOVARTIS AG	+6.69%	204B
ROCHE HOLDING AG	-5.93%	203B
PFIZER, INC.	-3.65%	160B

Other Pharmaceuticals